Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus.
Identifieur interne : 000174 ( Main/Exploration ); précédent : 000173; suivant : 000175Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus.
Auteurs : Chantal M. Morel [Suisse] ; Olof Lindahl [Suède] ; Stephan Harbarth [Suisse] ; Marlieke E A. De Kraker [Suisse] ; Suzanne Edwards [Allemagne] ; Aidan Hollis [Canada]Source :
- The Journal of antibiotics [ 1881-1469 ] ; 2020.
Abstract
The scarcity of novel antibiotic compounds in a time of increasing resistance rates has begun to ring alarm bells at the highest echelons of government. Large new financial incentives to accelerate antibiotic research and development, such as market entry rewards (MERs), are being considered. However, there is little focus on how to sustain the efficacy of new, promising antibiotics reaching the market. Currently, inappropriate use of antibiotics is commonplace, which has accelerated resistance development. In an attempt to halt this trend, antibiotic stewardship policies are being implemented in many resource-rich settings. Unfortunately, this has not yet had an impact on the amount of antibiotics being prescribed globally. One important hurdle is misalignment of incentives. While governments and health services are incentivized to promote prudent use of this common good, pharmaceutical companies are incentivized to increase volume of sales to maximize profits. This problem must be addressed or else the major efforts going into developing new antibiotics will be in vain. In this paper we outline an approach to realign the incentives of pharmaceutical companies with wider antibiotic conservation efforts by making a staged bonus a component of an MER for antibiotic developers when resistance to their drug remains low over time. This bonus could address the lack of stewardship focus in any innovation-geared incentive.
DOI: 10.1038/s41429-020-0300-y
PubMed: 32203126
Affiliations:
- Allemagne, Canada, Suisse, Suède
- Alberta, Berlin, East Middle Sweden, Svealand
- Berlin, Calgary, Uppsala
- Université d'Uppsala, Université de Calgary
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000138
- to stream PubMed, to step Curation: 000138
- to stream PubMed, to step Checkpoint: 000172
- to stream Ncbi, to step Merge: 002636
- to stream Ncbi, to step Curation: 002636
- to stream Ncbi, to step Checkpoint: 002636
- to stream Main, to step Merge: 000177
- to stream Main, to step Curation: 000174
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus.</title><author><name sortKey="Morel, Chantal M" sort="Morel, Chantal M" uniqKey="Morel C" first="Chantal M" last="Morel">Chantal M. Morel</name><affiliation wicri:level="1"><nlm:affiliation>University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland. Chantal.Morel@unige.ch.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Lindahl, Olof" sort="Lindahl, Olof" uniqKey="Lindahl O" first="Olof" last="Lindahl">Olof Lindahl</name><affiliation wicri:level="4"><nlm:affiliation>Department of Business Studies, Uppsala University, Kyrkogårdsgatan 10C Box 513, 751 20, Uppsala, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Business Studies, Uppsala University, Kyrkogårdsgatan 10C Box 513, 751 20, Uppsala</wicri:regionArea><orgName type="university">Université d'Uppsala</orgName><placeName><settlement type="city">Uppsala</settlement><region nuts="1">Svealand</region><region nuts="1">East Middle Sweden</region></placeName></affiliation></author><author><name sortKey="Harbarth, Stephan" sort="Harbarth, Stephan" uniqKey="Harbarth S" first="Stephan" last="Harbarth">Stephan Harbarth</name><affiliation wicri:level="1"><nlm:affiliation>Infection Control Programme and Division of Infectious Diseases, University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil, 41205, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Infection Control Programme and Division of Infectious Diseases, University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil, 41205, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="De Kraker, Marlieke E A" sort="De Kraker, Marlieke E A" uniqKey="De Kraker M" first="Marlieke E A" last="De Kraker">Marlieke E A. De Kraker</name><affiliation wicri:level="1"><nlm:affiliation>University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Edwards, Suzanne" sort="Edwards, Suzanne" uniqKey="Edwards S" first="Suzanne" last="Edwards">Suzanne Edwards</name><affiliation wicri:level="3"><nlm:affiliation>Department of Health Care Management, Berlin University of Technology, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Health Care Management, Berlin University of Technology, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Hollis, Aidan" sort="Hollis, Aidan" uniqKey="Hollis A" first="Aidan" last="Hollis">Aidan Hollis</name><affiliation wicri:level="4"><nlm:affiliation>Department of Economics, University of Calgary, 2500 University Dr NW, Calgary, AB, T2N1N4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Economics, University of Calgary, 2500 University Dr NW, Calgary, AB, T2N1N4</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32203126</idno><idno type="pmid">32203126</idno><idno type="doi">10.1038/s41429-020-0300-y</idno><idno type="wicri:Area/PubMed/Corpus">000138</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000138</idno><idno type="wicri:Area/PubMed/Curation">000138</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000138</idno><idno type="wicri:Area/PubMed/Checkpoint">000172</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000172</idno><idno type="wicri:Area/Ncbi/Merge">002636</idno><idno type="wicri:Area/Ncbi/Curation">002636</idno><idno type="wicri:Area/Ncbi/Checkpoint">002636</idno><idno type="wicri:Area/Main/Merge">000177</idno><idno type="wicri:Area/Main/Curation">000174</idno><idno type="wicri:Area/Main/Exploration">000174</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus.</title><author><name sortKey="Morel, Chantal M" sort="Morel, Chantal M" uniqKey="Morel C" first="Chantal M" last="Morel">Chantal M. Morel</name><affiliation wicri:level="1"><nlm:affiliation>University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland. Chantal.Morel@unige.ch.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Lindahl, Olof" sort="Lindahl, Olof" uniqKey="Lindahl O" first="Olof" last="Lindahl">Olof Lindahl</name><affiliation wicri:level="4"><nlm:affiliation>Department of Business Studies, Uppsala University, Kyrkogårdsgatan 10C Box 513, 751 20, Uppsala, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Business Studies, Uppsala University, Kyrkogårdsgatan 10C Box 513, 751 20, Uppsala</wicri:regionArea><orgName type="university">Université d'Uppsala</orgName><placeName><settlement type="city">Uppsala</settlement><region nuts="1">Svealand</region><region nuts="1">East Middle Sweden</region></placeName></affiliation></author><author><name sortKey="Harbarth, Stephan" sort="Harbarth, Stephan" uniqKey="Harbarth S" first="Stephan" last="Harbarth">Stephan Harbarth</name><affiliation wicri:level="1"><nlm:affiliation>Infection Control Programme and Division of Infectious Diseases, University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil, 41205, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Infection Control Programme and Division of Infectious Diseases, University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil, 41205, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="De Kraker, Marlieke E A" sort="De Kraker, Marlieke E A" uniqKey="De Kraker M" first="Marlieke E A" last="De Kraker">Marlieke E A. De Kraker</name><affiliation wicri:level="1"><nlm:affiliation>University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Edwards, Suzanne" sort="Edwards, Suzanne" uniqKey="Edwards S" first="Suzanne" last="Edwards">Suzanne Edwards</name><affiliation wicri:level="3"><nlm:affiliation>Department of Health Care Management, Berlin University of Technology, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Health Care Management, Berlin University of Technology, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Hollis, Aidan" sort="Hollis, Aidan" uniqKey="Hollis A" first="Aidan" last="Hollis">Aidan Hollis</name><affiliation wicri:level="4"><nlm:affiliation>Department of Economics, University of Calgary, 2500 University Dr NW, Calgary, AB, T2N1N4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Economics, University of Calgary, 2500 University Dr NW, Calgary, AB, T2N1N4</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation></author></analytic><series><title level="j">The Journal of antibiotics</title><idno type="eISSN">1881-1469</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The scarcity of novel antibiotic compounds in a time of increasing resistance rates has begun to ring alarm bells at the highest echelons of government. Large new financial incentives to accelerate antibiotic research and development, such as market entry rewards (MERs), are being considered. However, there is little focus on how to sustain the efficacy of new, promising antibiotics reaching the market. Currently, inappropriate use of antibiotics is commonplace, which has accelerated resistance development. In an attempt to halt this trend, antibiotic stewardship policies are being implemented in many resource-rich settings. Unfortunately, this has not yet had an impact on the amount of antibiotics being prescribed globally. One important hurdle is misalignment of incentives. While governments and health services are incentivized to promote prudent use of this common good, pharmaceutical companies are incentivized to increase volume of sales to maximize profits. This problem must be addressed or else the major efforts going into developing new antibiotics will be in vain. In this paper we outline an approach to realign the incentives of pharmaceutical companies with wider antibiotic conservation efforts by making a staged bonus a component of an MER for antibiotic developers when resistance to their drug remains low over time. This bonus could address the lack of stewardship focus in any innovation-geared incentive.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Canada</li><li>Suisse</li><li>Suède</li></country><region><li>Alberta</li><li>Berlin</li><li>East Middle Sweden</li><li>Svealand</li></region><settlement><li>Berlin</li><li>Calgary</li><li>Uppsala</li></settlement><orgName><li>Université d'Uppsala</li><li>Université de Calgary</li></orgName></list><tree><country name="Suisse"><noRegion><name sortKey="Morel, Chantal M" sort="Morel, Chantal M" uniqKey="Morel C" first="Chantal M" last="Morel">Chantal M. Morel</name></noRegion><name sortKey="De Kraker, Marlieke E A" sort="De Kraker, Marlieke E A" uniqKey="De Kraker M" first="Marlieke E A" last="De Kraker">Marlieke E A. De Kraker</name><name sortKey="Harbarth, Stephan" sort="Harbarth, Stephan" uniqKey="Harbarth S" first="Stephan" last="Harbarth">Stephan Harbarth</name></country><country name="Suède"><region name="Svealand"><name sortKey="Lindahl, Olof" sort="Lindahl, Olof" uniqKey="Lindahl O" first="Olof" last="Lindahl">Olof Lindahl</name></region></country><country name="Allemagne"><region name="Berlin"><name sortKey="Edwards, Suzanne" sort="Edwards, Suzanne" uniqKey="Edwards S" first="Suzanne" last="Edwards">Suzanne Edwards</name></region></country><country name="Canada"><region name="Alberta"><name sortKey="Hollis, Aidan" sort="Hollis, Aidan" uniqKey="Hollis A" first="Aidan" last="Hollis">Aidan Hollis</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000174 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000174 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32203126
|texte= Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32203126" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |